The peritoneovenous shunt: expectations and reality.
Moskovitz M.
Am J Gastroenterol. 1990 Aug;85(8):917-29.
Peritoneovenous shunt as a palliative option in generalized lymphatic anomaly.
Fuke N, Nishisho S, Tanaka A, Shimono R, Kusaka T.
Pediatr Int. 2021 Dec;63(12):1532-1534. doi: 10.1111/ped.14646. Epub 2021 Aug 18.
Peritoneovenous Shunt for Intractable Ascites in Children: A Series of 4 Cases.
Defert C, Marret JB, Lacaille F, Sissaoui S, Dupic L, Lardy H, Capito C, Chardot C.
J Pediatr Gastroenterol Nutr. 2021 Jul 1;73(1):e7-e10. doi: 10.1097/MPG.0000000000003131.
Mitigation of Sarcopenia after Peritoneovenous Shunt Placement in Patients with Refractory Ascites.
Currie BM, Bakhtiar M, Nadolski GJ, Soulen MC.
J Vasc Interv Radiol. 2023 Apr;34(4):633-638. doi: 10.1016/j.jvir.2022.12.037. Epub 2022 Dec 20.
The place of the peritoneovenous shunt in the treatment of ascites.
LeVeen EG, LeVeen HH.
ASAIO Trans. 1989 Apr-Jun;35(2):165-8. doi: 10.1097/00002480-198904000-00011.
Use of Peritoneovenous Shunt for the Management of Refractory Ascites.
Ayllón MD, Ciria R, Gómez-Luque I, Rodriguez-Perálvarez M, Padial A, Luque A, López-Cillero P, de la Mata M, Briceño J.
Transplant Proc. 2019 Jan-Feb;51(1):41-43. doi: 10.1016/j.transproceed.2018.04.089. Epub 2018 Jun 30.
Peritoneovenous shunt.
Sahi RP, Sinha KN, Mahendra NN.
Trop Gastroenterol. 1986 Jan-Mar;7(1):24-8.
[Clinical Study of Peritoneovenous Shunt for Patients with Refractory Ascites Accompanied with Hepatocellular Carcinoma].
Nakajima T, Aihara T, Ikuta S, Tomoo Y, Nomura K, Matsuki G, Fujikawa M, Ichise N, Kasai M, Okamoto R, Nakamoto Y, Yanagi H, Yamanaka N.
Gan To Kagaku Ryoho. 2022 Dec;49(13):1576-1578.
Therapeutic results of Denver percutaneous peritoneovenous shunt in cancer patients with malignant ascites.
Tamagawa H, Aoyama T, Inoue H, Fujikawa H, Sawazaki S, Numata M, Sato T, Oshima T, Yukawa N, Morimoto M, Ueno M, Rino Y, Masuda M.
J Cancer Res Ther. 2020 Dec;16(Supplement):S95-S98. doi: 10.4103/jcrt.JCRT_606_18.
[Role of peritoneovenous shunt therapy in end-of-life care of refractory malignant ascites cases].
Taniura T, Yamamoto T, Inoue K, Kishi T, Ishitobi K, Sato Y, Hidaka M.
Nihon Shokakibyo Gakkai Zasshi. 2023;120(12):1003-1011. doi: 10.11405/nisshoshi.120.1003.
